Refine by
T Cell Receptor Suppliers & Manufacturers
27 companies found
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T ...
based inSeoul, SOUTH KOREA
NGS industries are rapidly evolving and our customers are in greater need of technical support in various research fields and markets. Just like a chameleon utilizing its colored pigments and crystals to adapt to its surroundings, we proactively ...
Immune Repertoire often represents an individual’s current immuno- logical status, whether healthy, vaccinated, diseased or infected. Only the high-throughput NGS analysis could comprehensively profile an individual’s immune repertoire. ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. ...
based inNew Delhi, INDIA
Takara Bio companies provide kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. As a member of the Takara Bio Group, DSS Takara Bio India Private Ltd. is part of a company that holds ...
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an array of innovative ...
based inPleasanton, PENNSYLVANIA (USA)
10x Genomics is building tools for scientific discovery that reveal and address the true complexities of biology and disease. 10x Genomics products have been adopted by researchers around the world, including all of the top 100 global research ...
Consistent results: Reduce variability in single cell data, generating reproducible and consistent results. Maximum lab productivity: Free up hands-on time for other experiments with walk-away convenience for single cell workflows. Integrated and ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Pro5® MHC Class I Pentamers the most consistent, most published commercial technology for detecting antigen-specific CD8+ T cells. Pro5® MHC Pentamer. The beautiful rational design of Pro5® MHC Pentamers presents five MHC peptide ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inKraków, POLAND
Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced ...
Accelerate discovery and improve safety of TCR therapies using Artificial Intelligence. Following the unique opportunity for curing patients provided by the development of cell therapies (e.g. TCR discovery), Ardigen has set on the path to advance ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous ...
based inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
based inMawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the ...
based inSeattle, WASHINGTON (USA)
window into the adaptive immune system the world hadn’t thought possible. Together, Harlan and his brother Chad, founded Adaptive to meet the worldwide demand for immunosequencing technology. Over the past decade, we have developed our proprietary ...
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines. ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...